Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled double-blind study of donidalorsen for prevention of hereditary angioedema attacks
MOH_2022-07-27_011930Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of donidalorsen in hereditary angioedema (HAE) (4 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started Jul 2022; status: completed.
02
Drugs
donidalorsen
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2022-07-27_011930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-27_011930.